EACS2023: 514 Real life evidence on dual therapy with dolutegravir and lamivudine A.C.C. Iglessias , J.V.R. Madruga , M.V. Tancredi , L.R. Ramos , C.A. Moraes , A.F. da Costa , C.V. Mendes , E.M.N. Kalmar , F.L.N. Nogui , P.R. Müller , S.T.S. Leme , J.P.S. Gouveia , T.V.G. Souza , M. Sasaki , M. Fonsi , D.G. Carvalho , D.P. da Silva , M.F.F. de Medeiros , C. Rodrigues , R.S. Nogueira Centro de Referência e Treinamento DST/AIDS, Casa da Pesquisa, São Paulo, Brazil General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: Introduction: Toxicities related to the long-term use of antiretrovirals (ARVs) are a challenge in the current management of people living with HIV/AIDS (PLWHA). The introduction of more potent ARV presenting higher genetic barrier, became dual therapy (DT) an option to reduce reverse transcriptase inhibitors toxicities. Method: Methods: Retrospective analysis of PLWHA accompanied at the CRT DST/AIDS, São Paulo, under DT based on Dolutegravir 50mg + Lamivudine 300mg over 365 days. Data was captured from the medical records and ARV dispensing system and entered into the REDCAP platform. Variable analysis was performed using the STATA 17.0 program. Results: Results: Out of 8849 patients in the institution database, 383 were eligible. Population characteristics: cisgender men 294 (76.1%), White 284 (74.1%), college education 171 (44.6%), median age 56.9 years, mean time of HIV infection 16.9 years, mean time of ARVs exposure 13.5 years, mean number of previous ARVs regimens 3.1 and previous exposure to Integrase inhibitors 218 (56.9%). We identified 371 patients in follow-up, 9 deaths and 3 patients with missing data. The main reasons for DT were bone comorbidity 110 (28.7%), kidney comorbidity 95 (24.8%), and dosage convenience 86 (22.4%). 371(96.9%) patients were still under DT, 8 patients switched therapy (2 virological failures [heavily treated patients], one of each: ART optimization after blip, presence of M184V mutation in previous genotyping test, Hepatitis B infection resistant to Lamivudine and Entecavir, kidney dysfunction, tremors related to Parkinson’s Syndrome and medical decision) and 4 patients were missing data. Mean time of DT use was 2.4 years. It was not possible to assess the absence of previous virological failure in the entire population. Conclusions: Conclusion: Dual therapy comprising a medication with high genetic barrier and effectiveness, such as Dolutegravir, could be a safe treatment option for PLWHA under long-term antiretroviral therapy. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 128 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=